Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I)
Authors:
- Ren WenRWRen Wen
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (1) , 225-227
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Role of the GABA Transporter in Epilepsy2004
- GABA and Its Receptors in Epilepsy2004
- Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidusExperimental Brain Research, 2003
- Flumazenil, a GABA antagonist, may improve features of Parkinson's diseaseMovement Disorders, 2003
- The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's diseaseNeuroscience, 2000
- GABAA receptor pharmacologyPharmacology & Therapeutics, 1996
- The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidateJournal of Medicinal Chemistry, 1993
- γ‐Vinyl GABA (Vigabatrin): Relationship Between Dosage, Plasma Concentrations, Platelet GABA‐Transaminase Inhibition, and Seizure Reduction in Epileptic ChildrenEpilepsia, 1992
- A family of genes encoding neurotransmitter transporters.Proceedings of the National Academy of Sciences, 1992
- Cloning and Expression of a Rat Brain GABA TransporterScience, 1990